|
Post by mnkdfann on Feb 11, 2019 18:02:48 GMT -5
Just doing some research on this company BIOMM in Brazil.. Seems they haven't even submitted papers for approval yet. Don't hold your breath, albeit I'm sure it wouldn't take nearly as long to approve at this stage. Interesting that they have an article about diabetes (The relationship between sleep and diabetes) on their front page. Prepping for whats to come? BIOMM does not file for approval it's Mannkind. Brazil has already approved the Dreamboat device and waiting on Afrezza. Brazil flew to Danbury to inspect their facility over the summer. Another company of mine received approval from Brazil recently so hopefully they will be getting to Afrezza soon. Are you sure? Biomm and Mannkind jointly announced the submission of the registration dossier to ANVISA, and at the same time announced that Biomm was responsible for the registration of Afrezza with ANVISA: investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-biomm-submit-registration-dossier-brazilian-health
|
|
|
Brazil
Feb 11, 2019 17:48:33 GMT -5
Post by mnkdfann on Feb 11, 2019 17:48:33 GMT -5
Brazil is also preoccupied with Brazil. Last I heard / read, Brazilian President Bolsonaro is still recuperating in the hospital (after a bout with pneumonia) and some of his Ministers are taking the opportunity to plot against him.
|
|
|
Post by mnkdfann on Feb 11, 2019 17:44:05 GMT -5
Seems like things might been turning in MNKDs favor. Rxs seem to be reaching what might be considered higher lows. The annual lull in Jan and Feb seems to have recovered fastest to date. Further insurance coverage has come on line. Particularly in CA with Kaiser and Humana. And the continued onslaught of commercials has been steady. Just need the damn fuse to lite and stay lit. Be it another molecule, something cannabis related. Least anyone forget Brazil, India, or any other international sale, as they are not count in the weekly count, correct.Back to buying more weekly. Best to all. Afrezza is not really available in any of those countries (Brazil and India) yet, is it? Certainly in Brazil, approval is still forthcoming. AFAIK, India is no further ahead (I may be mistaken). So I think there is nothing from those countries to include in any weekly count.
|
|
|
Post by mnkdfann on Feb 11, 2019 15:17:18 GMT -5
VDex definitely knows how to utilize social media. Put out a repost of a diabetes-related article and readers are brought to your site. Good execution IMO. I give VDex credit for trying, but after 2 years it only has just over 650 followers on twitter. IMO it knows how to post on social media, but not how to really get much out of it.
|
|
|
RLS
Feb 11, 2019 15:07:09 GMT -5
Post by mnkdfann on Feb 11, 2019 15:07:09 GMT -5
The above FAQ also noted that some Mannkind employees on Mannkind's payroll would be tasked with doing work in support of RLS' activities. I'm sure Mannkind (not exactly rolling in cash to spare) would be more than happy if some or all of those employees were 'poached' by RLS and transferred to the payroll of RLS instead. Perhaps that explains any employee movement to RLS since 2016.
What are MannKind’s responsibilities in the licensing agreement? MannKind is responsible for transferring necessary technical information about the Technosphere platform to the licensee and then providing ancillary support as they develop their product on the Technosphere platform, and ultimately ramp up their manufacturing capability. To support these efforts, MannKind will name a team of existing scientific and manufacturing personnel to work with a corresponding team from the licensee, and a project plan will be implemented to manage the process. We anticipate no incremental costs to MannKind, just the costs of existing personnel.
|
|
|
Post by mnkdfann on Feb 10, 2019 10:09:22 GMT -5
ST....@bigcheeze 2/9/19, 8:17 AM @rooksleanne lee143 RLS is a $MNKD shell created by Al Mann.They both have almost identical addresses and same employees & same technology Mannkind officially denied the RLS shell company etc. rumours years ago in a FAQ it published at the time. Goodness knows where that FAQ is now hidden on the Mannkind site, but it still turns up if one googles the words: receptor life sciences faq mannkind license agreement From FAQ: "The licensing agreement is between MannKind and Receptor Life Sciences, Inc., an independent company, not affiliated with MannKind. The company is private and newly formed under this name. We can confirm that the company is funded by an important investor group, supported by prominent business leaders in the Seattle area. Alfred Mann is not an investor or in any way affiliated with Receptor."
|
|
|
Post by mnkdfann on Feb 8, 2019 16:52:25 GMT -5
Yes what is mnkd doing to target it’s message to mellenials and pwd in their late teens, early 20’s to 30’s. They are the tech savvy new adopters! Not sure they are watching CNN, Fox et al... this is where they should run ads on college campus networks, and fb, social media etc... Young people have told me that Facebook is now mostly for "older people" (like their parents and grandparents). Most of my Facebook Friends are in their 70s or 80s (like me). I have 30-year old relatives (nieces, nephews, and the like) and they are far more active on Facebook than I ever was. I'd say Facebook is still popular among those who were, say, 12 years and over about 15 years ago when Facebook started up. In my experience, people around age 30 and up are still active there. Under age 25, that is a different story. I think they gravitate more to Instagram, Snap, Twitter, Youtube, and such. This is in the U.K., but I think it probably (evidently according to the article) more or less applies in the U.S. as well: www.dailymail.co.uk/sciencetech/article-6105279/Snapchat-surges-popularity-people-turn-backs-Facebook-UK.html
|
|
|
Post by mnkdfann on Feb 8, 2019 9:04:13 GMT -5
Unfortunately, this endo is actually up-to-date when s/he states that Afrezza delivers less control than a pump. Why? Because there have been ZERO publications by MannKind in major medical journals to dispute what this endocrinologist has learned about inhaled insulin. The STAT results were published in by Kartish Garg MD in his diabetes journal, which has a smaller readership than Lancet, AMA or NEJM. This lack of current and available medical information is kicking MannKind in the rear end, IMO. For all the money being spent on DTC ads for Afrezza, what good will it do if the doctors refuse to prescribe it? Where are the new publications that Castagna/Kendall stated would soon be released? I believe the statement about upcoming medical publications was made at either the Cantor Fitzgerald Global Healthcare Conference on Oct 2, 2018 or the Rodman & Renshaw 20th Annual Global Investment Conference on Sept 5, 2018. Also, at the ASM in May 2018, they promised 16 publications in the months ahead. "Dr. Kendall ... stated that MannKind now has approximately 16 additional publications that will be coming out in the months ahead." mnkd.proboards.com/post/147727
|
|
|
Post by mnkdfann on Feb 7, 2019 19:57:19 GMT -5
|
|
|
Post by mnkdfann on Feb 5, 2019 14:50:24 GMT -5
We haven’t received any of those items in blue. Spencer’s latest article projects we don’t make it to next year. It does not include the 30m nor one of the milestone payments. Specifically, he says end of Q3 or start of Q4 2019. I'm not 100% sure how to interpret your "nor one of the milestone payments" comment. He certainly does include at least some milestone payments in his 2019 analysis. See his Cash Table footnotes. He also said he is underestimating ramped up advertising costs.
|
|
|
Post by mnkdfann on Feb 5, 2019 9:21:15 GMT -5
Here's hoping the empty 'pipeline' page is sufficient to attract investment dollars from some naive energy sector investors!!! It pains me that nobody liked my earlier post. Energy -> Oil - Pipeline. Too subtle?
|
|
|
Post by mnkdfann on Feb 5, 2019 9:16:46 GMT -5
I'm amused you didn't go back and just edit your original post instead of make another post drawing attention to your typo. You'd fit in with Mannkind IT.
|
|
|
Post by mnkdfann on Feb 4, 2019 18:39:50 GMT -5
Here's hoping the empty 'pipeline' page is sufficient to attract investment dollars from some naive energy sector investors!!!
|
|
|
Post by mnkdfann on Feb 4, 2019 10:52:31 GMT -5
AerBetic is still a work in progress. It is a nice idea, time will show if it evolves beyond vapourware. youtu.be/4mdm2JKwz_Q
|
|
|
Post by mnkdfann on Feb 3, 2019 20:40:34 GMT -5
It is now Feb 3rd and the direct purchase program officially ended 3 days ago. Whats the plan going forward? Is it being extended, ended or something else? I forgot or missed the fact that it was a January only offer. I wonder how close to 1,000 registrants they attracted. www.insulinsavings.com/"This offer is only available during the month of January for the first 1,000 registrants. See below for complete terms and conditions."
|
|